Study offers a differentiated patient-specific solution in minimal residual disease testing
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This compelling and technically distinct approach will help expand Exact Sciences leadership in precision oncology and offers a differentiated patient-specific solution in minimal residual disease testing.
Analysis of DNA shed into a patient s blood stream can provide a noninvasive means of detecting the presence of a tumor. Patients who have undergone initial treatment may only have small amounts of tumor DNA in their blood, which can be difficult to detect with conventional technology. TARDIS was developed to be highly sensitive and customizable for each patient, including those with only a trace amount of tumor remaining following surgery or other localized treat
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This compelling and technically distinct approach will help expand Exact Sciences leadership in precision oncology and offers a differentiated patient-specific solution in minimal residual disease testing.
/PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology.
Share:
The investigational vaccine is the first-of-its-kind for type 1 diabetes to be tested in the United States and showed positive results in an early study in Europe
A City of Hope Phase 1 trial featuring an investigational vaccine that uses a person s own immune cells, a beta cell protein and vitamin D3 to potentially treat type 1 diabetes is now recruiting patients. The trial is part of The Wanek Family Project for Type 1 Diabetes at City of Hope, which seeks to find cures for the disease.
Bart O. Roep, Ph.D., City of Hope s Chan Soon-Shiong Shapiro Distinguished Chair in Diabetes and director of The Wanek Family Project. (Photo: Business Wire)